SCM
NKTR icon

Soleus Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Soleus Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.96M Buy
+128,362
New +$9.39M 0.31% 60

Other funds holding NKTR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $156M AUM 183.17% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Soleus Capital Management's NKTR Position: Q2 2026 in Review

Soleus Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 128,362 shares worth $8.96M. The stake represents 0.31% of the portfolio and ranks #60 among its holdings.

83 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Soleus Capital Management held 128,362 shares of Nektar Therapeutics worth $8.96M as of Q2 2026.
  • Nektar Therapeutics was a new Soleus Capital Management position in Q2 2026.
  • Nektar Therapeutics made up 0.31% of Soleus Capital Management's portfolio in Q2 2026, its #60 holding.
  • 83 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.